MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pbc.28112

Медицинская библиотека · Pediatric blood & cancer · 2020

Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.

Shah Nirali N, Bhojwani Deepa, August Keith, Baruchel André, Bertrand Yves, Boklan Jessica, Dalla-Pozza Luciano, Dennis Robyn, Hijiya Nobuko, Locatelli Franco, Martin Paul L, Mechinaud Françoise, Moppett John, Rheingold Susan R, Schmitt Claudine, Trippett Tanya M, Liang Meina, Balic Kemal, Li Xia, Vainshtein Inna, Yao Nai Shun, Pastan Ira, Wayne Alan S

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical activity. A phase 2 study further evaluated efficacy.

PROCEDURE: This international, multicenter, phase 2 study enrolled children with relapsed/refractory B-cell precursor ALL who received moxetumomab pasudotox 40 µg/kg intravenously every other day, for six doses per 21-day cycle. The primary objective was to evaluate the complete response (CR) rate. Secondary objectives included safety, pharmacokinetics, and immunogenicity evaluations.

RESULTS

Thirty-two patients (median age, 10 years) were enrolled at 16 sites; 30 received study drug and were evaluable for safety; 28 were evaluable for response. The objective response rate was 28.6%, with three patients (10.7%) achieving morphologic CR, and five patients (17.9%) achieving partial response. Disease progression occurred in 11 patients (39.3%). Ten patients (33.3%) experienced at least one treatment-related serious adverse event, including capillary leak syndrome (CLS; n = 6), hemolytic uremic syndrome (HUS; n = 4), and treatment-related death (n = 1) from pulmonary edema. No differences were observed in inflammatory markers in patients who did or did not develop CLS or HUS.

CONCLUSIONS

Despite a signal for clinical activity, this phase 2 study was terminated at interim analysis for a CR rate that did not reach the stage 1 target. Preclinical data suggest enhanced efficacy of moxetumomab pasudotox via continuous infusion or in combination regimens; thus, further studies designed to optimize the efficacy and safety of moxetumomab pasudotox in pediatric ALL may be warranted.

Для цитирования: Shah Nirali N, Bhojwani Deepa, August Keith, Baruchel André, Bertrand Yves, Boklan Jessica, Dalla-Pozza Luciano, Dennis Robyn, Hijiya Nobuko, Locatelli Franco, Martin Paul L, Mechinaud Françoise, Moppett John, Rheingold Susan R, Schmitt Claudine, Trippett Tanya M, Liang Meina, Balic Kemal, Li Xia, Vainshtein Inna, Yao Nai Shun, Pastan Ira, Wayne Alan S. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.. Pediatric blood & cancer. 2020. DOI: 10.1002/pbc.28112.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.